Clinical Trial

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

Name: Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) — clinical trial record (NCT05248646)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

To Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy

Protocol Amendment History 2 changes

critical Trial completed 2026-06-04

minor Completion moved earlier: 2026-12-30 -> 2026-05-13 2026-06-04

Trial Details

NCT Number	NCT05248646
Lead Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions	Immunoglobulin A Nephropathy
Enrollment	530 participants
Start Date	2022-03-15
Primary Completion	2026-05-13 (estimated)
Study Completion	2027-01-19 (estimated)
Updated on ClinicalTrials.gov	2026-07-14